66326_S124
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- SPERMATOGENESIS+0.360
- PANCREAS_BETA_CELLS+0.280
- E2F_TARGETS+0.270
- XENOBIOTIC_METABOLISM+0.220
- KRAS_SIGNALING_DN+0.190
- BILE_ACID_METABOLISM+0.170
- G2M_CHECKPOINT+0.150
- FATTY_ACID_METABOLISM+0.030
- GLYCOLYSIS+0.030
- APICAL_SURFACE+0.000
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- ALLOGRAFT_REJECTION-0.460
- INTERFERON_GAMMA_RESPONSE-0.420
- WNT_BETA_CATENIN_SIGNALING-0.420
- IL6_JAK_STAT3_SIGNALING-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.380
- CHOLESTEROL_HOMEOSTASIS-0.370
- MYC_TARGETS_V2-0.360
- TGF_BETA_SIGNALING-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.882 |
| 2 | SAMN03290928 | — | — | 0.857 |
| 3 | TCGA-53-A4EZ-01A-12R-A24X-07 | — | cohortA3 | 0.854 |
| 4 | TCGA-E7-A7PW-01A-11R-A352-07 | — | — | 0.850 |
| 5 | TCGA-BB-4224-01A-01R-1436-07 | — | — | 0.845 |
| 6 | TCGA-FJ-A3ZF-01A-11R-A23N-07 | — | — | 0.842 |
| 7 | TCGA-95-7043-01A-11R-1949-07 | — | cohortA4 | 0.839 |
| 8 | SRR10899998 | — | — | 0.839 |
| 9 | sclc0624_S64.txt | — | cohortSC | 0.836 |
| 10 | TCGA-XF-A8HC-01A-11R-A36F-07 | — | — | 0.833 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| SPERMATOGENESIS | 0.360 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |